很好, 谨慎乐观.

有朋友母亲四十来岁时也曾得过肺癌. 而且不算早期了. 后来吃一种叫"泰素?"的化疗药治好了.
她也吃了不少灵芝, 冬虫夏草灵之类. 到现在一直没事.

所以CHAT还是要保持乐观. 只要没有扩散. 就有机会. 关键要保持乐观, 提高生命力, , 毕竟化疗很伤身体.

期待更多好消息!

今天GENENTECH(DNA)的新抗肺癌药, Avastin, 说能延长患者生命到12个月. 比以前10个月长些...

股票大涨25%.

晕！到现在才看到这贴。

建议，大量吃黑色食品。黑木耳，香菇，黑芝麻，黑糙米。。。。。。。。。

补血补气抗癌。

她老人家一定会没事的。现在科技那么发达了。

CHAT,

我一直不敢看这个题目. 可今早还是看了, 好沉重....!

ＧＯＤ　ＢＬＥＳＳ　ＹＯＵ！

为你和你妈妈祈祷!

冰花

看到关于癌症和体质的一篇文章：

三十多年前有一位服務於公賣局台北啤酒廠的張先生，參加該啤酒場選派技術人員到國外深造的考試，以優異的成績及格。在出國前經某公立醫院體檢發現，罹患有像小孩拳頭大小的肺部腫瘤，因而不能出國。張先生非常失望之餘，一直懷疑診斷有誤；於是再到另一家醫院檢查，結果還是證實原來的診斷並無錯誤。



當時年輕力壯的張先生得到這樣的絕症，在人生絕望之餘，多次打電話給當時任職台東縣政府黃順興縣長機要秘書的魏姓同學。魏姓同學便利用星期日趕到台北和張先生見面，張先生向魏同學詳述相關絕望的詳情和悲觀感受，並請位同學協助其後事，恰逢魏同學與前任馬偕醫院院長(1949－55年)專精於癌症臨床研究的呂革令博士係知交好友。當即建議前往訪求呂博士醫治，起初張先生說不願再看醫生，以免徒增傷悲；但魏同學說先前已以電話請教過呂博士並安排好時間，張先生只好偕同前往呂博士住處造訪。



呂博士和張先生見面就說： 「魏先生是我的好友，介紹你和我認識是我們緣份，感謝上帝賜給我們這個機會；我請教你：『癌為什麼叫絕症，你可知道嗎？』」

張先生和魏先生都不知道如何作答。呂博士又說：「人類醫治癌症到目前為止只有兩條路， 第一條路是消滅病源，第二條路是增加抵抗力。但很奇怪的是，癌無論用鈷60或其他藥物去消滅癌細胞，可是癌細胞還沒被消滅，好的細胞卻先被殺死。另無論用什麼營養、補藥，好的細胞還未吸收，癌細胞卻先吸收、讓癌長得更快；因此可說上述兩條路都行不通、所以叫絕症。」



呂博士又說：「人類的聰明連登陸月球也都已經成功，但為什麼沒有人去懷疑上述兩條治癌的路是在鑽牛角尖，另外找第三條路？感謝上帝賜給我以往在馬偕醫院做癌症方面的臨床實驗，並得院內各部同仁協助的機會，我發現癌症病人血液檢查的結果百分之百都是酸性反應。長期素食、且生活接近然的佛寺僧尼，由於體質都偏屬優質弱鹼性，所以尚沒有發現罹患癌症的病例。因此我大膽的斷定在弱鹼性體質的狀態下，癌細胞是無法生長、甚至是無法生存的。張先生我建議你從現在起少吃酸性的葷食類，多吃鹼性食物，另外可吃綠藻和帶殼菱角湯，改變你的體質，並勵行接近自然的良好生活規律；如果五年內不死、你就沒問題了，願上帝祝福你。」



張先生依照呂博士的建議，認真改變吃的習慣，每天又吃綠藻、喝菱角湯，樂觀加上每天適當的運動，一年後再到同一公立醫院檢查結果，發現腫瘤不但沒有長大、反而已呈現萎縮狀態，遂令醫院檢查人員驚為奇蹟，五年後竟完全處於萎縮、至近於消失狀態。



經過了將近四十年歲月，現在張先生的健康情況完全正常，生活起居甚為愉快。繼張先生之後，有位前台東省立醫院總務課長陳添壽先生，同樣得到肺癌；魏先生得知後將張先生的經過轉告陳添壽先生，陳先生乃依照呂博士的建議進行改變體質，結果與張先生同樣癒癌症。



那時呂博士全家已移民美國，事後呂博士回來台灣再與魏先生見面時，魏先生將張先生和陳先生的經過告訴呂博士，並提議由他們倆位親自向呂博士陳述，請呂博士發表其改變體質之自療成果報告。



呂博士謙虛地回答說： 「我年事已大，!且沒有臨床紀錄不能做為成果。請魏先生轉告親友，如果友人認同的話，請他們繼續做體驗並廣為宣導，感謝上帝。」





Part II. 85﹪癌症病患屬於酸性體質



＊   健康人的血液是成弱鹼性的，約是pH 7.35～7.45左右

＊   嬰兒也是屬於弱鹼性的體質

＊   成長期的成人有體質酸化的現象



根據一項六百位癌症病人體液分佈的研究，顯示85﹪癌症病患屬於酸性體質。因此，如何使體質維持在弱鹼性就是遠離疾病的第一步。



酸性體質的生理表徵

1.     皮膚無光澤。

2.     香港腳。

3.     稍做運動即感疲勞，一上公車便想睡覺。

4.     上下樓梯容易氣喘。

5.     肥胖、下腹突出。

6.     步伐緩慢、動作遲緩。




為什麼會形成酸性體質？

1.     過度攝取乳酸性食品
l   肉類、乳酪製品與蛋、牛肉、火腿等皆屬於酸性食品。

l   攝取過量的酸性食品血液會傾向酸性而變黏稠，不易流到細血管的末稍，而易造成手腳或膝蓋的冷寒症，以及肩膀僵硬和失眠等。

l   年輕力壯時吃適量的肉類是對的，但老年人則以蔬菜或小魚為宜。

2.     生活步調失常會造成酸性體質
l   生活步調失常會造成精神與肉體的壓力。

l   據統計，晚睡者罹患癌症的機率比正常人高出五倍。

l   人類本來就活在節奏的世界裡，無法事先儲備睡眠或飲食，也不能日夜顛倒。

l   人體內臟受自律神經控制，白天主要是交感神經活動，晚上則由副交感神經工作，若使其錯亂及倒置，就亦百病滋生。

3.     情緒過於緊張
l   文明社會會造成的壓力。

l   工作上或精神上的壓力。

l   當一個人承受精神壓力後，一旦緊張鬆弛，時會造成猝死，稱為潛在性副腎皮質機能不全症。

4.     肉體的緊張
l   動手術之前應先檢查腎上腺皮質機能是否正常。如果副腎皮質機能較差， 或手術壓力遠超過副腎調整功能， 則可能造成病人死亡或其他不良影響。

l   若發現病患臉部浮腫，需詳加詢問病史及服藥狀況，為長期服用腎上腺皮質賀爾蒙者，施以針灸要特別注意反應。

l   勞動或運動過度，通宵打牌、開車等壓力都應盡量避免。






常見食物的酸鹼性

強酸性食品
蛋黃、乳酪、白糖做的西點或柿子、烏魚子、柴魚等。

中酸性食品
火腿、培根、雞肉、鮪魚、 豬肉、鰻魚、牛肉、麵包、小麥、奶油、馬肉等。

弱酸性食品
白米、落花生、啤酒、酒、 油炸豆腐、海苔、文蛤、章魚、泥鰍。

弱鹼性食品
紅豆、蘿蔔、蘋果、甘藍菜、 洋蔥、豆腐等。

中鹼性食品
蘿蔔乾、大豆、紅蘿蔔、蕃茄、 香蕉、橘子、南瓜、草莓、蛋白、梅乾、檸檬、菠菜等。

強鹼性食品
葡萄、茶葉、葡萄酒、海帶芽、海帶等。 尤其是天然綠藻富含葉綠素，是不錯的鹼性健康食品，而茶類不宜過量，最佳飲用時間為早上。

给chat和chat妈妈加油！

佩服你们的毅力和乐观的精神，相信chat妈妈一定会战胜病魔的！

没什么经验可供参考，但是我会虔诚地为你们祈祷！

.............................................

ＣＨＡＴ，

先为你妈妈能控制住病情而欣慰，　希望她老人家一天天好起来。
继续祈祷！

看到你说的“妈妈因为从小神经性头痛，所以很久以来一直依赖止痛片，一直到后来一个--神婆---给她治好以后。”我眼睛一亮呀。我从十三岁开始受神经性头痛的折磨，每每发作，杀了自己的心都有。你那神婆我要到哪里去找呀，　如果她能帮我治好我的头痛，我一定会乐到天上去了。。。

嗯。妈妈治病大概10年以前，现在那个神婆是否还给普通人看病，或者是否还在我都不知道了。我可以帮你问一下他们单位的人，可以给我留个邮件么？那个单位是军方高级技术单位,不便公开。

还有，原来我妈妈试过用天麻和瘦肉煮了吃。有些缓解。

神经性头痛很难受的，我小时候看着妈妈怎么过来的。trouble，你能够这么照顾一家人，一定很不容易。你也一定保持一个好心情啊！不要太操心，操劳了。

谢ＣＨＡＴ！

请看短信！

troublemaker
没有收到你的短信啊。

引用

下面是引用chat于2005-03-21 03:50发表的:
troublemaker
没有收到你的短信啊。

呵呵，茶包说的短信不在你的手机里，当然也不在移动电话里，而是在论坛里给你的短信，在页面右上角 控制面板 · · 短消息 · 查看新贴，这个短消息用于本论坛朋友只间传递一些私人的信息，只有收件人可以看到(相当于一个小信箱吧！)。

茶包已经在短信中告诉了你她的email地址，请你跟她联系(不是说只有收件人可以看到吗？我怎么就知道了呢？)。

咦？我这么热心论坛建设，怎么着也该享受一个副科级待遇吧？是该跟老大反应一下我的职称职务问题了。呵呵。。。

我是看了这里的短信啊。有别人的，可是没有troublemaker的。。

写好，　忘了发了。

拉出去，　暴打一顿！



看样子老伍很知道我的情况地说。。。

以下是你的职务职称问题的批示：

交董事会研究决议！

Source: University Of Pennsylvania Medical Center
Date: 2004-08-05
URL: http://www.sciencedaily.com/releases/2004/08/040805091402.htm

--------------------------------------------------------------------------------

Penn Researchers Offer New Hope To Advanced Stage Lung Cancer Patients
Philadelphia, PA -- A new study that appears in the June 2004 issue of the Journal of Clinical Oncology shows that the life-expectancy of patients with advanced stage lung cancer can be extended with the use of photodynamic therapy, or PDT, in addition to surgical intervention. Typically, advanced stage non-small cell lung cancer patients have a median survival of 6-9 months when treated with the current standard of care, chemotherapy alone. However, this same set of patients demonstrated a median survival of more than 22 months when chemotherapy was combined with surgery and intraoperative PDT, a new laser-based cancer treatment. Joseph S. Friedberg, MD, Chief of Thoracic Surgery at Presbyterian-University of Pennsylvania Medical Center, Stephen Hahn, MD, Clinical Associate Professor of Radiation Therapy and James P. Stevenson, MD, Assistant Professor of Medicine are the co-investigators in this trial at the University of Pennsylvania Medical Center.

“We consider these results preliminary but extremely encouraging. We expected PDT to make a difference in the rate of local recurrence and it has,” says Dr. Friedberg, “However, we did not anticipate the dramatic increase in survival that we have observed. In addition to the local control, there must be some sort of systemic immune response that is contributing to the enhanced survival we are observing in these patients with a very advanced form of the disease. We are exploring this phenomenon at a number of levels and feel we may have stumbled upon the makings of a new immunologic approach to treating patients with all stages of lung cancer. It is an area of research about which we are very excited and actively pursuing.”

In PDT, a nontoxic photosensitizing agent, Photofrin, is injected into the blood stream and concentrates in cancer cells, allowing the cancer to become very sensitive to light. Using a laser to shine light on these cells results in a very effective mechanism for killing cancer cells. The damage occurs only where the light is shined, limiting the harm to healthy tissue. PDT has rarely been used in this way, combining it with other treatment modalities, although it has been used by clinicians for treating small, easily visualized tumors in the windpipe and esophagus. Patients eligible for the treatment are those whose cancer has spread within the chest cavity.

In the study, each patient is treated with chemotherapy until the cancer stops responding, the normal course for this disease and the limitation of chemotherapy alone. After it is confirmed that the cancer has not spread beyond the chest cavity, the patient then receives Photofrin 24 hours prior to surgery. During surgery, the cancer is removed, which may involve excising all or part of the affected lung. Then, surgeons shine a laser into the chest cavity, giving the appropriate dose of light in an effort to kill any remaining microscopic tumor cells that remain after surgery.

It is known that surgery, without PDT, will almost certainly be accompanied by a high rate of local recurrence, likely a result of the invisible remaining disease being targeted with PDT. The treatment has proven very safe, largely as a function of using a specially designed computer system to measure and monitor the amount of laser light delivered at the time of treatment.

Editor's Note: The original news release can be found here.

Source: Washington University School Of Medicine
Date: 2004-04-19
URL: http://www.sciencedaily.com/releases/2004/04/040415010103.htm

--------------------------------------------------------------------------------

Lung Tumor Therapies Improved By Combining CT And PET Scans
St. Louis, April 14, 2004 -- Physicians targeting lung tumors for radiation therapy can substantially improve their aim by combining data from two scanning techniques, according to Washington University researchers at Siteman Cancer Center and Barnes-Jewish Hospital in St. Louis.

The current standard practice is to devise radiation therapy targets based solely on computerized tomography (CT) scans, which produce detailed pictures of the size and shape of cancerous growths.

In a study in the April 15 issue of the International Journal of Radiation, Oncology, Biology, Physics, researchers show that adding data from positron emission tomography (PET) scans to structural CT data significantly enhances radiologists' abilities to precisely define the locations of tumors for radiation treatments. Radiologists use PET to get detailed information on tissue function and activity, enabling them to highlight such differences as the increased metabolic activity of a tumor.

For the study, researchers compared therapy plans designed by different physicians for 26 lung cancer patients. Two therapy plans were devised for each patient: A physician with access only to CT scanning results created one of the plans, while another physician independently created a second therapy plan based on combined data from CT and PET scans. Patients had non-small-cell lung cancer, the most common type of lung tumor.

"Adding the PET data to the analysis changed and improved the treatment plans 58 percent of the time," says lead investigator Jeffrey D. Bradley, M.D., assistant professor of radiation oncology. "PET-CT helped physicians more accurately identify where tumors were in patients, and that's very important to efficacy of treatment and to limiting side effects."

As an example of improved effectiveness, Bradley cited a patient whose tumor had caused a lung to collapse. With a CT scan only, physicians had identified a significant portion of the collapsed lung as tumor. However, with a combined PET-CT image, they were able to show that the tumor was much smaller.

Combined PET-CT scanning units, first devised approximately two years ago, are now available at hundreds of hospitals nationwide, according to Bradley.

"Papers like this are intended both to help change the community standard for how radiation treatment protocols are designed and to change insurers' willingness to pay for this new approach," Bradley says. "This is the next advance in radiology, and it could be very helpful to our patients."

Bradley is designing a multi-institutional follow-up study for the Radiation Therapy Oncology Group, a cooperative group funded by the National Cancer Institute.

###


Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA, Bosch W, Bertrand RJ. Impact of FDG-PET on Radiation Therapy Volume Delineation in Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, April 15, 2004.

Funding from the Siteman Cancer Center supported this research.

The full-time and volunteer faculty of Washington University School of Medicine are the physicians and surgeons of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked second in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.

test

Gene Mutation Predicts Outcome For Lung Cancer Patients
Patients with the earliest form of the most common type of lung cancer are more than twice as likely to die of the disease within four years if they have a mutation in a well known cancer-causing gene, scientists have found. The study in the July 2 issue of the Journal of the National Cancer Institute also shows that lung cancer patients who both smoke and consume alcohol frequently are more likely to have the mutation.
A team led by surgeon Steven A. Ahrendt, M.D., of the James P. Wilmot Cancer Center at the University of Rochester analyzed tumors from 188 patients with non-small-cell lung cancer. The team found that the status of the p53 gene plays a pivotal role in distinguishing which patients are most likely to survive four years or more. The discovery comes at a time when complex molecular markers are beginning to play a role along with more traditional features such as the extent of cancer in a patient's body in determining the treatments that cancer patients receive.
"We need to confirm these results through a larger study, but this difference is large enough to be clinically meaningful," says Ahrendt, associate professor of surgery, oncology, and pathology.
The ability to predict which patients are more likely to live or die could cause doctors to re-think how they treat certain lung cancer patients Ahrendt says. Currently, patients with early-stage lung cancer commonly receive surgery but not chemotherapy or radiation unless the cancer recurs. If scientists know that certain patients – for instance, those with a p53 mutation – are much more likely to die of the disease, preventive chemotherapy might be considered earlier in treatment.
The study creates a bright spot for a disease where the overall survival rate is dismal. Lung cancer is the leading cause of death by cancer in both men and women, and overall, fewer than one in five patients live five years after diagnosis. For people whose lung cancer is caught in the earliest stage, the news is somewhat better: Generally about 40 to 60 percent of such patients live five years. Ahrendt's study identifies a sub-group of patients – those whose cancer is caught early, who don't have a p53 mutation – in which 78 percent of patients, nearly four in five, lived four years or more, a survival rate four times higher than for lung cancer patients overall.
Ahrendt and colleagues base the findings on an extensive study of tumor samples from 188 patients with non-small-cell lung cancer, which make up 80 percent of lung cancers. The team found mutations of the p53 gene – a gene whose normal function is to produce a protein that helps repair or destroy damaged cells before they can become troublesome – in 55 percent of the tumors. In the study, 48 percent of early-stage lung cancer patients with a p53 mutation died within four years, compared to 22 percent of patients without the mutation.
The team found that the type of p53 mutation matters as well. Patients with mutations that simply substituted one chemical base for another fared better than patients with more complicated mutations that completely knocked out the function of the tumor-suppressing protein made by p53.
The finding pertains only to those patients with very early lung cancer, which has not spread to lymph nodes or any other organs. The status of the p53 gene does not appear as crucial for later-stage cancers, probably because mutations in the p53 gene are overshadowed by the larger number of genetic abnormalities in these tumors.
The scientists also found that people who smoked and consumed alcohol frequently were 50 percent more likely to carry the mutation than smokers who did not regularly drink alcohol. While it's widely known that most people who get lung cancer are smokers, the evidence points out that once they get lung cancer, smokers who drink alcohol are more prone to have p53 mutations that make it more likely that they will die from the disease.
Ahrendt says the results of several dozen other studies that have looked at the relationship between p53 and lung cancer have varied widely, with some suggesting a link between p53 and survival, and others finding no such link. Some of the factors that set apart the current study, Ahrendt says, are its large size and its design as a "prospective" study in which scientists did not know the patient outcomes when the study began.
Most important, he says, the team used two very different techniques to check p53. In addition to conventional sequencing technology to check whether p53 had mutated, the team also used gene-chip technology to analyze the gene's genetic sequence. Together the techniques picked up more p53 mutations than previous studies.
Currently there is no easy, inexpensive blood test to check one's p53 status, Ahrendt says. The molecule is a popular pharmaceutical target for drugs in development because it's involved in many types of cancerous tumors, including breast, ovarian, bladder, brain and prostate cancers.
Other authors on the paper include researcher Yingchuan Hu and statistician Michael McDermott of the University of Rochester, and David Sidransky, Martin Buta, Nicole Benoit, Stephen C. Yang, and Li Wu of Johns Hopkins. With funding from the National Cancer Institute, the team analyzed tumors from patients where Ahrendt previously worked, at Johns Hopkins in Baltimore and at the Medical College of Wisconsin in Milwaukee.

This story has been adapted from a news release issued by University Of Rochester Medical Center.

.............................................